KR20070034132A - 알렌드로네이트 나트륨의 신규 수화물 형태, 이의 제조방법 및 이의 약학 조성물 - Google Patents

알렌드로네이트 나트륨의 신규 수화물 형태, 이의 제조방법 및 이의 약학 조성물 Download PDF

Info

Publication number
KR20070034132A
KR20070034132A KR1020077004456A KR20077004456A KR20070034132A KR 20070034132 A KR20070034132 A KR 20070034132A KR 1020077004456 A KR1020077004456 A KR 1020077004456A KR 20077004456 A KR20077004456 A KR 20077004456A KR 20070034132 A KR20070034132 A KR 20070034132A
Authority
KR
South Korea
Prior art keywords
alendronate
sodium
mixture
crystalline
alendronic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020077004456A
Other languages
English (en)
Korean (ko)
Inventor
니나 핀켈슈타인
라미 리도-하다스
주디스 아론힘
Original Assignee
테바 파마슈티컬 인더스트리즈 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 테바 파마슈티컬 인더스트리즈 리미티드 filed Critical 테바 파마슈티컬 인더스트리즈 리미티드
Publication of KR20070034132A publication Critical patent/KR20070034132A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/3804—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
    • C07F9/3839—Polyphosphonic acids
    • C07F9/3873—Polyphosphonic acids containing nitrogen substituent, e.g. N.....H or N-hydrocarbon group which can be substituted by halogen or nitro(so), N.....O, N.....S, N.....C(=X)- (X =O, S), N.....N, N...C(=X)...N (X =O, S)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Rheumatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
KR1020077004456A 1998-08-27 1999-08-27 알렌드로네이트 나트륨의 신규 수화물 형태, 이의 제조방법 및 이의 약학 조성물 Ceased KR20070034132A (ko)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US9831398P 1998-08-27 1998-08-27
US60/098,313 1998-08-27
US12974399P 1999-04-16 1999-04-16
US60/129,743 1999-04-16
US14446199P 1999-07-19 1999-07-19
US60/144,461 1999-07-19
PCT/US1999/019838 WO2000012517A1 (en) 1998-08-27 1999-08-27 Novel hydrate forms of alendronate sodium, processes for manufacture thereof, and pharmaceutical compositions thereof

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020017002535A Division KR20010079701A (ko) 1998-08-27 1999-08-27 알렌드로네이트 나트륨의 신규한 수화형, 이것의 제조방법 및 이것의 약학 조성물

Publications (1)

Publication Number Publication Date
KR20070034132A true KR20070034132A (ko) 2007-03-27

Family

ID=27378576

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020077004456A Ceased KR20070034132A (ko) 1998-08-27 1999-08-27 알렌드로네이트 나트륨의 신규 수화물 형태, 이의 제조방법 및 이의 약학 조성물
KR1020017002535A Ceased KR20010079701A (ko) 1998-08-27 1999-08-27 알렌드로네이트 나트륨의 신규한 수화형, 이것의 제조방법 및 이것의 약학 조성물

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020017002535A Ceased KR20010079701A (ko) 1998-08-27 1999-08-27 알렌드로네이트 나트륨의 신규한 수화형, 이것의 제조방법 및 이것의 약학 조성물

Country Status (30)

Country Link
US (2) US6281381B1 (enExample)
EP (1) EP1107974B1 (enExample)
JP (2) JP2002523514A (enExample)
KR (2) KR20070034132A (enExample)
AT (1) ATE334993T1 (enExample)
AU (1) AU5698899A (enExample)
BG (1) BG65329B1 (enExample)
BR (1) BR9913472A (enExample)
CA (1) CA2341459A1 (enExample)
CZ (1) CZ2001629A3 (enExample)
DE (1) DE69932620T2 (enExample)
DK (1) DK1107974T3 (enExample)
EA (1) EA002739B1 (enExample)
EE (1) EE04552B1 (enExample)
ES (1) ES2270613T3 (enExample)
HR (1) HRP20010129A2 (enExample)
HU (1) HUP0203078A3 (enExample)
IL (1) IL141423A (enExample)
IS (1) IS5864A (enExample)
LT (1) LT4888B (enExample)
LV (1) LV12720B (enExample)
NO (1) NO20010957L (enExample)
NZ (1) NZ510682A (enExample)
PL (1) PL346347A1 (enExample)
PT (1) PT1107974E (enExample)
RO (1) RO122854B1 (enExample)
SI (1) SI20581B (enExample)
SK (1) SK2482001A3 (enExample)
WO (1) WO2000012517A1 (enExample)
YU (1) YU14701A (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1406910B1 (fr) * 2001-07-16 2010-01-13 Universite Paris 13 Procedes de preparation de derives de bisphosphonates
GB2383042A (en) * 2001-10-18 2003-06-18 Cipla Ltd Amorphous alendronate sodium
US20040052843A1 (en) * 2001-12-24 2004-03-18 Lerner E. Itzhak Controlled release dosage forms
HUP0600680A3 (en) * 2001-12-24 2008-04-28 Teva Pharma Dosage form with a core tablet of active ingredient sheathed in a compressed annular body of powder or granular material, and process and tooling for producing it
ITMI20020146A1 (it) * 2002-01-29 2003-07-29 Lyogen Ltd Alendronato monosodico amorfo e processo per la sua preparazione
JP2005531532A (ja) * 2002-04-05 2005-10-20 メルク　エンド　カムパニー　インコーポレーテッド アレンドロナートおよびビタミンｄ製剤を用いる骨吸収阻害法
US20080249068A1 (en) * 2002-09-05 2008-10-09 Deluca Hector F Method of Extending the Dose Range of Vitamin D Compounds
WO2005035542A1 (en) * 2003-10-14 2005-04-21 Pliva-Istrazivanje I Razvoj D.O.O. Solid-state form of alendronate sodium and preparation thereof
US20050181043A1 (en) * 2004-02-12 2005-08-18 Indranil Nandi Alendronate salt tablet compositions
US20050261250A1 (en) * 2004-05-19 2005-11-24 Merck & Co., Inc., Compositions and methods for inhibiting bone resorption
DK1753395T3 (da) 2004-05-24 2010-11-08 Warner Chilcott Co Llc Enterisk, fast, oral doseringsform af et bisphosphonat, der indeholder et chelateringsmiddel
CZ296937B6 (cs) * 2004-09-02 2006-07-12 Zentiva, A. S Trisodná sul kyseliny 4-amino-1-hydroxybutyliden-1,1-bisfosfonové
ES2331015T3 (es) * 2004-10-29 2009-12-18 Sandoz Ag Proceso para la preparacion de un glatiramero.
US20060134190A1 (en) * 2004-12-16 2006-06-22 Banner Pharmacaps Inc. Formulations of bisphosphonate drugs with improved bioavailability
CZ297262B6 (cs) * 2004-12-28 2006-10-11 Zentiva, A. S. Trisodná sul kyseliny 4-amino-1-hydroxybutyliden-1,1-bisfosfonové
US8003820B2 (en) * 2005-10-20 2011-08-23 Dr. Reddy's Laboratories Limited Process for preparing bisphosphonic acids
AR058168A1 (es) * 2005-11-07 2008-01-23 Merck & Co Inc Sintesis del alendronato de sodio trihidratado
NZ589053A (en) * 2006-10-27 2012-03-30 Signal Pharm Llc Process of preparing 4-[9-(tetrahydro-furan-3-yl)-8-(2,4,6-trifluoro-phenylamino)-9h-purin-2-ylamino]-cyclohexan-1-ol compounds
JP5244608B2 (ja) * 2006-11-22 2013-07-24 エーザイ・アール・アンド・ディー・マネジメント株式会社 二糖類化合物のナトリウム塩及びその製造方法並びにその使用
US20090118238A1 (en) * 2007-09-17 2009-05-07 Protia, Llc Deuterium-enriched alendronate
US20090076144A1 (en) * 2007-09-17 2009-03-19 Protia, Llc Deuterium-enriched bazedoxifene
US20090170815A1 (en) * 2007-12-28 2009-07-02 Roxane Laboratories Incorporated. Alendronate oral liquid formulations
US8629178B2 (en) * 2009-11-03 2014-01-14 Li Liu Sodium tanshinone IIA sulfonate hydrate and preparation method and use thereof
SG10202012791TA (en) 2013-11-15 2021-01-28 Akebia Therapeutics Inc Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3016289A1 (de) 1980-04-28 1981-10-29 Henkel KGaA, 4000 Düsseldorf Verfahren zur herstellung von omega -amino-1-hydroxyalkyliden-1,1-bis-phosphonsaeuren
IT1201087B (it) 1982-04-15 1989-01-27 Gentili Ist Spa Bifosfonati farmacologicamente attivi,procedimento per la loro preparazione e relative composizioni farmaceutiche
US4639338A (en) * 1984-08-06 1987-01-27 Ciba-Geigy Corporation Preparation of crystalline disodium 3-amino-1-hydroxypropane-1,1-diphosphonate pentahydrate
DE3434667A1 (de) 1984-09-21 1986-04-03 Henkel KGaA, 4000 Düsseldorf 4-dimethylamino-1-hydroxybutan-1,1-diphosphonsaeure, deren wasserloesliche salze, verfahren zu ihrer herstellung sowie ihre verwendung
IT1196315B (it) * 1984-10-29 1988-11-16 Gentili Ist Spa Procedimento per la preparazione di acidi difosfonici
US4711800A (en) * 1985-06-06 1987-12-08 Divincenzo Maureen Needlecraft with metallic substrate
US4922007A (en) * 1989-06-09 1990-05-01 Merck & Co., Inc. Process for preparing 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid or salts thereof
US5019651A (en) * 1990-06-20 1991-05-28 Merck & Co., Inc. Process for preparing 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid (ABP) or salts thereof
US5039819A (en) 1990-09-18 1991-08-13 Merck & Co., Inc. Diphosphonate intermediate for preparing an antihypercalcemic agent
US5159108A (en) 1990-09-18 1992-10-27 Merck & Co., Inc. Process for preparing an antihypercalcemic agent
CA2221844A1 (en) 1995-06-06 1996-12-12 Merck & Co., Inc. Disodium alendronate formulations
DK0833643T3 (da) * 1995-06-06 2005-05-30 Merck & Co Inc Formuleringer af vandfrit mononatriumsalt af alendronat og deres anvendelse til behandling af knoglesygdomme

Also Published As

Publication number Publication date
HUP0203078A2 (hu) 2003-01-28
US20030065214A1 (en) 2003-04-03
BR9913472A (pt) 2002-03-05
EP1107974A1 (en) 2001-06-20
DK1107974T3 (da) 2006-10-30
EE04552B1 (et) 2005-10-17
US6281381B1 (en) 2001-08-28
EA002739B1 (ru) 2002-08-29
NO20010957L (no) 2001-04-26
JP2009143955A (ja) 2009-07-02
SI20581B (sl) 2008-06-30
AU5698899A (en) 2000-03-21
IL141423A (en) 2005-09-25
DE69932620T2 (de) 2006-12-14
HUP0203078A3 (en) 2005-01-28
SK2482001A3 (en) 2002-01-07
EA200100184A1 (ru) 2001-10-22
RO122854B1 (ro) 2010-03-30
EE200100126A (et) 2002-06-17
LT2001016A (en) 2001-10-25
KR20010079701A (ko) 2001-08-22
EP1107974A4 (en) 2001-09-26
LV12720B (en) 2002-02-20
LV12720A (lv) 2001-09-20
WO2000012517A9 (en) 2000-07-13
US6696601B2 (en) 2004-02-24
HRP20010129A2 (en) 2005-04-30
JP2002523514A (ja) 2002-07-30
IS5864A (is) 2001-02-26
DE69932620D1 (de) 2006-09-14
PT1107974E (pt) 2006-10-31
CA2341459A1 (en) 2000-03-09
YU14701A (sh) 2003-01-31
WO2000012517A1 (en) 2000-03-09
EP1107974B1 (en) 2006-08-02
ATE334993T1 (de) 2006-08-15
SI20581A (sl) 2001-12-31
IL141423A0 (en) 2002-03-10
PL346347A1 (en) 2002-02-11
NO20010957D0 (no) 2001-02-26
NZ510682A (en) 2003-09-26
CZ2001629A3 (cs) 2001-08-15
LT4888B (lt) 2002-02-25
BG65329B1 (bg) 2008-02-29
BG105292A (en) 2001-12-29
ES2270613T3 (es) 2007-04-01

Similar Documents

Publication Publication Date Title
KR20070034132A (ko) 알렌드로네이트 나트륨의 신규 수화물 형태, 이의 제조방법 및 이의 약학 조성물
KR20110066197A (ko) 스트론튬 라넬레이트의 무수물 및 수화물 형태
US6963008B2 (en) Hydrate forms of alendronate sodium, processes for manufacture thereof, and pharmaceutical compositions thereof
EP1702924A2 (en) Novel hydrate forms of alendronate sodium, processes for manufacture thereof, and pharmaceutical compositions thereof
AU2004202301B2 (en) Novel hydrate forms of alendronate sodium, processes for manufacture thereof, and pharmaceutical compositions thereof
MXPA01002017A (en) Novel hydrate forms of alendronate sodium, processes for manufacture thereof, and pharmaceutical compositions thereof
JP3637019B2 (ja) 新規な結晶性パミドロン酸二ナトリウム水和物及びその製造方法
CN116355015B (zh) 一种唑来膦酸的制备方法
AU2020289084B2 (en) Process for the preparation of the polymorph f of sodium neridronate
US20090149427A1 (en) Pharmaceutically acceptable salts and hydrates of risedronic acid
JP3205816B2 (ja) 結晶性エトポシド４’−ホスフェートジエタノレート
CZ20041249A3 (cs) Trisodná sul kyseliny 4-amino-1-hydroxybutyliden-1,1-bisfosfonové

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

R18 Changes to party contact information recorded

Free format text: ST27 STATUS EVENT CODE: A-3-3-R10-R18-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000